A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System

NCT00475566 | Completed DMC

• 1 other identifier: 06-103
• Study Type: interventional
• Target: 104
• Locations: 4 countries
• Sites: 10

Brief Summary

The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal lesions. Abbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The decision to discontinue the study is not related to any safety concern. The rationale for this proposal is based on the following considerations: The performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and no stent fractures, and the rate of additional revascularizations has been stable since approximately 14 months after the procedure. Evaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature show low rates of death, reintervention and stent fracture, which are consistent with STRIDES and demonstrate the safety of the nitinol stent platform of the DYNALINK-E. Long-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E - everolimus tissue concentration drops below the quantifiable limit by approximately 17 months after implant, and vascular response to the coating is normal with widely patent lumens and struts incorporated into vessel tissue. The safety and performance of the DYNALINK-E has been substantiated by its clinical and pre-clinical data, and by the clinical data of similar products. Given the demonstrated mechanical integrity of the stent along with the evidence of a healthy long-term vascular response, there is a reasonable expectation of continued low event rates.

Conditions

Atherosclerosis; Peripheral Vascular Disease

Outcome Measures

Primary Outcomes (1)

• In-stent binary restenosis (>50% stenosis), as measured by duplex ultrasound

  6 months

Secondary Outcomes (3)

• Angiographic in-stent binary restenosis rate (>50%)

  12 months

• Angiographic mean in-stent late loss, in-stent mean minimum lumen diameter (MLD), percent diameter stenosis

  12 months

• Primary, and secondary patency

  1, 6, 12, 18 months, 2, 3, 4, 5 years

Study Arms (1)

1

OTHER

This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.

Device: Dynalink®-E everolimus-eluting peripheral stent; Device: Dynalink®-E, everolimus-eluting peripheral stent

Interventions

Dynalink®-E, everolimus-eluting peripheral stent DEVICE

Stenting of atherosclerotic de novo or restenotic lesions (\> 50% stenosis) in the native superficial femoral or proximal popliteal artery

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Rutherford Becker Category 2-5
• Single de novo or restenotic lesion in the superficial femoral or proximal popliteal artery
• Disease segment length 30-170 mm
• \>50% diameter stenosis or total occlusion
• Target reference vessel diameter 4.3-7.3 mm

You may not qualify if:

• Target lesion previously treated with stent or surgery
• Rutherford Becker Category 0, 1, or 6
• Immunosuppressive disorder or currently receiving immunosuppressive agents
• Serum creatinine \>2.5 mg/dl

Sponsors & Collaborators

• Abbott Medical Devices: lead

Study Sites (10)

Landeskrankenhaus Klagenfurt

Klagenfurt, 9020, Austria

Location

Allgemeines Krankenhaus der Stadt Wien- AKH Wien

Vienna, 1090, Austria

Location

Sint Blasius Hospital

Dendermonde, Belgium

Location

ZOL St. Jan

Ghent, 3600, Belgium

Location

University Hospital

Ghent, 9000, Belgium

Location

Herzzentrum Bad Krozingen

Bad Krozingen, 79189, Germany

Location

The Jewish Hospital Berlin

Berlin, 13347, Germany

Location

Herzzentrum Leipzig

Leipzig, 04289, Germany

Location

University Hospital Tübingen

Tübingen, 72076, Germany

Location

Casa di Cura di Montevergine

Mercogliano, 83013, Italy

Location

Related Publications (2)

• Lammer J, Scheinert D, Vermassen F, Koppensteiner R, Hausegger KA, Schroe H, Menon RM, Schwartz LB. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. J Vasc Surg. 2012 Feb;55(2):400-5. doi: 10.1016/j.jvs.2011.08.048. Epub 2011 Nov 1.

  PMID: 22051872 DERIVED

• Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011 Aug;54(2):394-401. doi: 10.1016/j.jvs.2011.01.047. Epub 2011 Jun 12.

  PMID: 21658885 DERIVED

MeSH Terms

Conditions

Atherosclerosis; Peripheral Vascular Diseases

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Johannes Lammer, M.D.

  Allgemeines Krankenhaus der Stadt Wien

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: May 16, 2007
• First Posted: May 21, 2007
• Study Start: May 1, 2007
• Primary Completion: July 1, 2008
• Study Completion: February 1, 2010
• Last Updated: March 10, 2011

Record last verified: 2011-03

Locations

DE (4); IT (1); AU (2); BE (3)